BG
TXG icon

Bellevue Group’s 10x Genomics TXG Stock Holding History

Bellevue Group’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10M Sell
261,470
-68,022
-21% -$1.78M 0.21% 71
2026
Q1 		$7M Buy
329,492
+7,432
+2% +$149K 0.17% 66
2025
Q4 		$5.25M Buy
322,060
+8,224
+3% +$124K 0.1% 73
2025
Q3 		$3.67M Sell
313,836
-12,915
-4% -$168K 0.08% 84
2025
Q2 		$3.78M Buy
326,751
+95,754
+41% +$873K 0.08% 86
2025
Q1 		$2.02M Sell
230,997
-39,731
-15% -$501K 0.05% 101
2024
Q4 		$3.89M Sell
270,728
-11,153
-4% -$176K 0.07% 99
2024
Q3 		$6.36M Sell
281,881
-26,430
-9% -$546K 0.1% 95
2024
Q2 		$6M Hold
308,311
– – 0.1% 95
2024
Q1 		$11.6M Buy
308,311
+15,138
+5% +$665K 0.18% 89
2023
Q4 		$16.4M Sell
293,173
-1,259
-0.4% -$54.8K 0.25% 81
2023
Q3 		$12.1M Sell
294,432
-30,314
-9% -$1.58M 0.2% 85
2023
Q2 		$18.1M Hold
324,746
– – 0.26% 82
2023
Q1 		$18.1M Hold
324,746
– – 0.26% 83
2022
Q4 		$11.8M Buy
324,746
+70,612
+28% +$2.31M 0.16% 94
2022
Q3 		$7.24M Sell
254,134
-5,237
-2% -$200K 0.1% 104
2022
Q2 		$11.7M Buy
259,371
+6,512
+3% +$338K 0.17% 101
2022
Q1 		$19.2M Buy
252,859
+20,187
+9% +$1.77M 0.22% 94
2021
Q4 		$34.7M Hold
232,672
– – 0.36% 80
2021
Q3 		$33.9M Hold
232,672
– – 0.34% 87
2021
Q2 		$45.6M Buy
232,672
+3,633
+2% +$657K 0.44% 70
2021
Q1 		$41.5M Buy
229,039
+63,916
+39% +$11M 0.44% 74
2020
Q4 		$23.4M Buy
165,123
+11,134
+7% +$1.62M 0.27% 94
2020
Q3 		$19.2M Buy
153,989
+30,912
+25% +$3.24M 0.27% 90
2020
Q2 		$11M Buy
123,077
+29,230
+31% +$2.28M 0.16% 100
2020
Q1 		$5.85M Sell
93,847
-35,280
-27% -$2.75M 0.11% 111
2019
Q4 		$9.85M Buy
129,127
+29,127
+29% +$1.75M 0.16% 90
2019
Q3 		$5.04M Buy
+100,000
New +$5.53M 0.09% 110

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bellevue Group's TXG Position: Q2 2026 in Review

Bellevue Group reduced its 10x Genomics (TXG) stake by 21% in Q2 2026, selling an estimated $1.78M and leaving 261,470 shares worth $10M. The position accounts for 0.21% of the portfolio, ranked #71.

Bellevue Group first reported a position in TXG in Q3 2019 and has held it in 28 quarters since. The position peaked at $45.6M in Q2 2021. 392 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

  • Bellevue Group held 261,470 shares of 10x Genomics worth $10M as of Q2 2026.
  • Bellevue Group sold 68,022 10x Genomics shares in Q2 2026, an estimated $1.78M.
  • 10x Genomics made up 0.21% of Bellevue Group's portfolio in Q2 2026, its #71 holding.
  • Bellevue Group first reported a position in 10x Genomics in Q3 2019 and has held it in 28 quarters since.
  • Bellevue Group's 10x Genomics position peaked at $45.6M in Q2 2021.
  • 392 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on Bellevue Group's 13F filing for Q2 2026, filed 14 Aug 2026.